AU2019222736B2 - Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis - Google Patents

Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis Download PDF

Info

Publication number
AU2019222736B2
AU2019222736B2 AU2019222736A AU2019222736A AU2019222736B2 AU 2019222736 B2 AU2019222736 B2 AU 2019222736B2 AU 2019222736 A AU2019222736 A AU 2019222736A AU 2019222736 A AU2019222736 A AU 2019222736A AU 2019222736 B2 AU2019222736 B2 AU 2019222736B2
Authority
AU
Australia
Prior art keywords
ibutamoren
alcoholic
drug
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019222736A
Other languages
English (en)
Other versions
AU2019222736A1 (en
Inventor
Roy G. Smith
Michael Oliver Thorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumos Pharma Inc
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Publication of AU2019222736A1 publication Critical patent/AU2019222736A1/en
Application granted granted Critical
Publication of AU2019222736B2 publication Critical patent/AU2019222736B2/en
Priority to AU2024205599A priority Critical patent/AU2024205599A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019222736A 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis Active AU2019222736B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205599A AU2024205599A1 (en) 2018-02-14 2024-08-07 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630361P 2018-02-14 2018-02-14
US62/630,361 2018-02-14
PCT/US2019/017964 WO2019161025A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205599A Division AU2024205599A1 (en) 2018-02-14 2024-08-07 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Publications (2)

Publication Number Publication Date
AU2019222736A1 AU2019222736A1 (en) 2020-07-30
AU2019222736B2 true AU2019222736B2 (en) 2024-08-01

Family

ID=67620042

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019222736A Active AU2019222736B2 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
AU2024205599A Pending AU2024205599A1 (en) 2018-02-14 2024-08-07 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205599A Pending AU2024205599A1 (en) 2018-02-14 2024-08-07 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Country Status (10)

Country Link
US (3) US20210059993A1 (enExample)
EP (3) EP4623929A3 (enExample)
JP (3) JP2021513552A (enExample)
KR (2) KR20240015742A (enExample)
CN (2) CN118453597A (enExample)
AU (2) AU2019222736B2 (enExample)
BR (1) BR112020016613A2 (enExample)
CA (1) CA3088177A1 (enExample)
EA (1) EA202091464A1 (enExample)
WO (1) WO2019161025A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799562B1 (en) 2019-03-29 2020-10-13 The General Hospital Corporation GHRH or analogues thereof for use in treatment of hepatic disease
KR20230079001A (ko) * 2020-09-18 2023-06-05 서울대학교산학협력단 비알코올성 지방간염 및 간 섬유화의 치료를 위한 약학적 조성물
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법
GEAP202516774A (en) * 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
CN119405782A (zh) * 2025-01-06 2025-02-11 山东大学 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
WO2005042003A1 (en) * 2003-10-24 2005-05-12 Merck & Co., Inc. Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
CA2603295A1 (en) * 2004-04-07 2006-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
SG10201902137PA (en) * 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
CA2998509A1 (en) * 2015-09-16 2017-03-23 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2019008554A1 (en) * 2017-07-06 2019-01-10 Conte Anthony METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE

Also Published As

Publication number Publication date
JP2024028337A (ja) 2024-03-04
EP4467158A3 (en) 2025-02-19
CN118453597A (zh) 2024-08-09
KR20200121308A (ko) 2020-10-23
EP4623929A2 (en) 2025-10-01
EA202091464A1 (ru) 2020-12-07
US20230381158A1 (en) 2023-11-30
AU2019222736A1 (en) 2020-07-30
CA3088177A1 (en) 2019-08-22
JP2021513552A (ja) 2021-05-27
AU2024205599A1 (en) 2024-08-22
EP3781158A1 (en) 2021-02-24
US20210059993A1 (en) 2021-03-04
EP3781158A4 (en) 2022-03-16
EP4623929A3 (en) 2025-12-17
EP4467158A2 (en) 2024-11-27
CN111727041A (zh) 2020-09-29
KR20240015742A (ko) 2024-02-05
JP2025179056A (ja) 2025-12-09
WO2019161025A1 (en) 2019-08-22
US20250281470A1 (en) 2025-09-11
BR112020016613A2 (pt) 2020-12-22

Similar Documents

Publication Publication Date Title
AU2019222736B2 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
US11116756B2 (en) Methods of treating pancreatic cancer
RU2523552C2 (ru) Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета
LeVarge Prostanoid therapies in the management of pulmonary arterial hypertension
TW200522952A (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
Amin et al. Emerging drugs for cystic fibrosis
EP3897647B1 (en) Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
CN115811972A (zh) 肝脏病症的组合治疗
US20170354657A1 (en) Method of treating pancreatic cancer
US12226526B2 (en) Mycophenolate oral suspension
WO2004039322A2 (en) Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
Charoo et al. Biowaiver monograph for immediate-release solid oral dosage forms: sitagliptin phosphate monohydrate
WO2021016369A1 (en) Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US20160151406A1 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
IL265034B2 (en) inhibition of olig2 activity
Cazzola et al. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease
Zeitlin Emerging drug treatments for cystic fibrosis
US20180028510A1 (en) Prevention and treatment of thrombosis in medically ill patients
CN111821303A (zh) 沃替西汀及其盐在制备抗肿瘤药物中的应用
CN108186658A (zh) 一种乙酰氨基阿维菌素缓释剂及其制备方法和应用
EP4212159A1 (en) Use of sphingosine-1-phosphate receptor agonist
CN102781238A (zh) Tivozanib和坦罗莫司的组合
Moretz Drug Class Update: Antipsychotics New Drug Evaluation: LYBALVI (olanzapine/samidorphan) oral tablets
AU2022277580A1 (en) Psychotropic agents and uses thereof
Grassi et al. P. 3. c. 020 Obsessive-compulsive disorder and hypochondriasis in schizophrenic patients treated with clozapine vs other atypical antipsychotics

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)